info@nsiv.org
North Shore InnoVenturesNorth Shore InnoVenturesNorth Shore InnoVenturesNorth Shore InnoVentures
  • Home
  • About NSIV
    • What Is
    • Impact
    • Our Team
    • Board of Directors
  • Incubation
    • Facilities
    • Equipment
    • Programs
  • Companies & Community
    • Incubated Companies
    • Resources
      • Jobs
      • Post a Job
      • Manage Job Listings
    • Our Sponsors
  • News & Events
  • Get Involved
    • Sponsorship
    • Mentorships
    • Internships
    • Join the Staff
  • Contact
Previous

Adeptrix Closes Series A Financing to Commercialize BAMS Technology

18 January, 2021

January 11, 2021 11:00 AM (Eastern Standard Time)

BEVERLY, MA (Scipreneur) Adeptrix Corp, the developer of advanced bioanalytical tools based on its proprietary BAMS™ (Bead Assisted Mass Spectrometry) platform technology, today announced the closing of its Series A investment round with Bruker Corporation as a new minority investor. The proceeds will go toward accelerating commercialization of multiple BAMS products and establishing custom BAMS assay development service for pharma, clinical, and food-science customers. The National Institutes of Health recently awarded funding to Adeptrix through the Rapid Acceleration of Diagnostics (RADx) initiative’s RADx Tech program to develop tools for accurate, rapid and easy-to-use COVID diagnostics. The Adeptrix BAMS assay will be used for the direct detection of SARS-CoV-2 virus infection by targeting viral proteins such as the spike glycoprotein and the nucleocapsid protein, and it also can be expanded to enable routine use of MALDI MS for other viruses to advance future clinical virology research.

Highly specific immunoassay platform for MALDI-TOF MS applications

Adeptrix’ BAMS technology is a multiplexed immunoassay platform for targeted analysis of proteins and protein fragments by MALDI-TOF mass spectrometry.  By measuring each immunoassay in thousands of channels using MALDI mass spectrometry, BAMS delivers greater analytical precision and specificity for drug discovery, diagnostics, and food safety testing applications. BAMS allows detection of protein biomarkers that have remained inaccessible to the conventional immunoassays and PCR-mediated tests, including post-translational modifications, point mutations and protein degradation products that play a key role in developmental and disease biology.

Dr. Vladislav Bergo, Chief Executive Officer at Adeptrix, said: “We are excited to partner with Bruker to pursue the next stage in our company’s growth and make Adeptrix products available to customers worldwide.  The timing is right to facilitate integration of MALDI-based mass spectrometry into protein immunoassays for development of high precision analytical solutions, as it enables monitoring important functional and regulatory changes within proteins that occur during disease progression.”

Dr. Jeffrey C. Silva, Chief Technology Officer at Adeptrix, added: “In the area of neurodegenerative disorders, including Alzheimer’s disease, BAMS MALDI-MS was able to monitor various levels of heterogeneity of key biomarkers such as beta-amyloid and tau protein in cerebrospinal fluid fractions (CSF) and brain tissue, to distinguish between normal and disease states. This demonstrates the potential of BAMS technology for biomarker validation studies as thousands of samples can be quickly analyzed both at the protein or the peptide level, and converted into a rapid test.”

Dr. Rohan A. Thakur, EVP of Life Sciences Mass Spectrometry at Bruker Daltonics, commented: “Our partnership with Adeptrix is important as it enables wider access to critical BAMS assay technology for translational research using MALDI-TOF mass spectrometry, which is capable of analyzing thousands of samples per day.  Our partnership is expected to accelerate collaborations with developers of antibodies and other affinity reagents to expand the range of available protein biomarker Affi-BAMS assays for liquid biopsies, cell and tissue-based applications.”

About Adeptrix Corp – https://www.adeptrix.com/

Adeptrix Corp is a developer and manufacturer of analytical reagents and assays that are based on the company’s proprietary platform technology termed Bead Assisted Mass Spectrometry (BAMS). BAMS™ is an innovative and powerful analytical platform that allows immunoassays to be measured by MALDI mass spectrometry for rapid, precise and sensitive target analyte detection. The BAMS platform technology is both multiplexed (capable of measuring multiple target analytes in a single assay) and high-throughput (capable of measuring hundreds to thousands of assays per day), making it amenable for a wide range of bio-analytical applications in drug development, basic research and clinical diagnostics. The current inventory of BAMS reagents have been configured for protein analysis in the fields of neurology, oncology and epigenetics. Over 30 assays are planned for release in Q1 2021.

Adeptrix will develop and commercialize BAMS assay kits for virology research and clinical diagnostics, both directly and via its strategic partners’ worldwide sales and marketing teams. The assays will be developed specifically to leverage the large installation base of MALDI instruments in Pharma and Academia.

https://www.adeptrix.com/pdf/2020_ASMS_ADX-JCS%20Poster_051520_FINAL_1220pm-a.pdf

Leave a Comment

Cancel reply

Your email address will not be published. Required fields are marked *

NSIV
100 Cummings Center
Suite 451C
Beverly, MA | 01915

Tour our facilities and be sure to ask about our cutting-edge equipment.

Schedule Now

Post Archive

  • January 2021 (3)
  • December 2020 (1)
  • November 2020 (1)
  • October 2020 (1)
  • September 2020 (1)
  • August 2020 (1)
  • June 2020 (5)
  • May 2020 (1)
  • April 2020 (3)
  • January 2020 (1)
  • November 2019 (2)
  • October 2019 (1)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (1)
  • June 2019 (2)
  • May 2019 (2)
  • April 2019 (2)
  • March 2019 (2)
  • February 2019 (2)
  • January 2019 (2)
  • November 2018 (2)
  • October 2018 (5)
  • August 2018 (3)
  • July 2018 (4)
  • June 2018 (3)
  • May 2018 (2)
  • April 2018 (4)
  • March 2018 (5)
  • February 2018 (2)
  • January 2018 (6)
  • December 2017 (2)
  • November 2017 (6)
  • October 2017 (4)
  • September 2017 (1)
  • August 2017 (1)
  • July 2017 (1)
  • June 2017 (1)
  • May 2017 (2)
  • April 2017 (3)
  • March 2017 (4)
  • February 2017 (2)
  • January 2017 (1)
  • December 2016 (1)
  • October 2016 (1)
  • September 2016 (2)
  • August 2016 (4)
  • July 2016 (1)
  • June 2016 (7)
  • May 2016 (4)
  • April 2016 (2)
  • March 2016 (6)
  • February 2016 (6)
  • January 2016 (3)
  • November 2015 (4)
  • October 2015 (2)
  • September 2015 (3)
  • August 2015 (2)
  • July 2015 (1)
  • June 2015 (8)
  • March 2015 (1)
  • February 2015 (2)
  • January 2015 (2)
  • December 2014 (2)
  • November 2014 (4)
  • October 2014 (5)
  • September 2014 (3)
  • August 2014 (3)
  • July 2014 (2)
  • June 2014 (6)
  • May 2014 (5)
  • April 2014 (3)
  • March 2014 (7)
  • January 2014 (4)
  • December 2013 (2)
  • November 2013 (2)
  • October 2013 (6)
  • September 2013 (1)
  • August 2013 (1)
  • July 2013 (1)
  • June 2013 (3)
  • May 2013 (2)
  • April 2013 (8)
  • March 2013 (4)
  • February 2013 (4)
  • January 2013 (3)
  • December 2012 (8)
  • November 2012 (7)
  • October 2012 (6)
  • September 2012 (15)
  • August 2012 (5)
  • July 2012 (4)
  • June 2012 (1)
  • January 2012 (2)

  • You may also like

    North Shore InnoVentures receives $200K+ EDA Grant

    Read now
  • You may also like

    Entrepreneur U: Smart Marketing for Emerging Companies

    Read now
  • You may also like

    Clean Energy Alliance Announces Award to North Shore InnoVentures from DOE-CEA Partnership

    Read now
  • You may also like

    Innoventures U: The Ins and Outs of Technology Licensing

    Read now
  • You may also like

    NSIV Grad Making More News

    Read now
  • You may also like

    July’s Innoventures U – A Great Primer on Tech Licensing

    Read now
  • You may also like

    BIVC Highlighted

    Read now
  • You may also like

    Next Innoventures U: August 16

    Read now

North Shore InnoVentures
100 Cummings Center
Suite 451C
Beverly, MA | 01915
978-867-0600

Apply for Incubation Space

Interested in incubating your company with NSIV? Submit your application today!

APPLY FOR A SPACE

Stay in the Know

Copyright 2017 © North Shore InnoVentures Inc. | All Rights Reserved | info@nsiv.org
  • Home
  • About NSIV
    • What Is
    • Impact
    • Our Team
    • Board of Directors
  • Incubation
    • Facilities
    • Equipment
    • Programs
  • Companies & Community
    • Incubated Companies
    • Resources
      • Jobs
      • Post a Job
      • Manage Job Listings
    • Our Sponsors
  • News & Events
  • Get Involved
    • Sponsorship
    • Mentorships
    • Internships
    • Join the Staff
  • Contact
North Shore InnoVentures